WHO publishes global hepatitis report: over 300 million people carry hepatitis B or hepatitis C virus
April 27, 2017 Source: Chinese Journal of Science
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];The World Health Organization released a new report on April 21 in Geneva, Switzerland, saying that more than 300 million people worldwide carry chronic hepatitis B virus or hepatitis C virus, and most people do not have access to appropriate testing and treatment. The challenge requires a global emergency response. The report also halved the number of people carrying the hepatitis C virus worldwide, but this decline has nothing to do with the recent emergence of powerful drugs to treat the disease.
The WHO Global Hepatitis Report estimates that in 2015, 71 million people were carrying the hepatitis C virus, a figure that was lower than the previous estimate of 130 million to 150 million. As explained in this report, this dramatic decline is mainly due to the test's focus on the measurement of the hepatitis C virus genetic material ribonucleic acid (RNA). Previous epidemiological investigations mainly tested whether people carried antibodies against the virus, and this method was inaccurate.
The report estimates that 257 million people worldwide are infected with the hepatitis B virus, a figure that is very close to previous estimates. Although hepatitis B virus and hepatitis C virus are irrelevant, they can lurk for decades without being noticed, and may eventually lead to cirrhosis or liver cancer.
Overall, these viruses caused a total of 1.34 million deaths in 2015. The report emphasizes that this figure is comparable to the number of TB deaths and is higher than the number of AIDS deaths. However, tuberculosis and AIDS mortality are declining and hepatitis mortality is rising.
WHO Director-General, Dr Margaret Chan, said: "Viral hepatitis is now seen as a major public health challenge and requires an urgent response. Vaccines and drugs to address hepatitis have already existed, and WHO is committed to ensuring that these tools cover all The person in need."
According to the report, among the five different types of hepatitis, hepatitis B and hepatitis C are the two main types, and 96% of hepatitis deaths are caused by hepatitis B and hepatitis C. However, despite the increase in the number of hepatitis deaths, the number of new hepatitis B infections has declined as children's hepatitis B vaccination coverage has increased. Globally, 84% of children born in 2015 were vaccinated with three recommended doses of hepatitis B vaccine.
The report said that despite the challenges of dealing with hepatitis, some countries are taking effective measures to prevent hepatitis. In 2015, China achieved a high coverage of 96% in the timely injection of the first dose of hepatitis B vaccine at the time of birth, reaching the goal of hepatitis B control with a prevalence of less than 1% for children under 5 years of age.
The WHO report states that diagnostic methods for detecting antibodies are much simpler than testing for viruses, which are rare in many countries that have been hit hard by hepatitis. The report estimates that only 14 million people know they have been infected with the hepatitis C virus. “The current situation may be that there are more problems in diagnostic testing than in the treatment of hepatitis,†said Yvan Hutin, a hepatologist at the World Health Organization in Geneva, Switzerland, who wrote the report.
Ana Maria Henao-Restrepo, an immunologist at the World Health Organization in Geneva, said that “we are happy but not satisfied with the coverage of the hepatitis B virus vaccineâ€. In particular, although 84% of babies worldwide now receive the recommended 3-needle dose, only 39% of babies are able to take the first dose within 24 hours of delivery.
“The dose after birth is crucial because most mother-to-child transmission occurs within a few days after birth,†says Henao-Restrepo. “We need to make sure that all countries – not just half of them – are The baby is able to provide this life-saving vaccine when he is born."
According to the report, infants are at risk of being infected even if they receive birth doses because their mothers actively replicate hepatitis B virus during childbirth. Administration of antiviral drugs to pregnant women infected with hepatitis B virus can reduce the risk of infection in infants.
In general, Hutin believes that such intervention may mean, "Soon, children's hepatitis B will become history." (Zhao Xixi)
Ulipristal Acetate Intermediates
Dingmin Pharmaceutical supply Ulipristal Acetate API and Ulipristal Acetate Intermediates with high purity and best price. The main products CAS No are as follows: 126784-99-4, 54201-84-2, 14340-01-3, 126690-41-3, 14340-04-6, 159811-51-5, 33300-19-5. Sample can be sent if you request.
Welcome to do business with us. Please email to us directly.
Gestadienol Acetate,Ulipristal Acetate Intermediates,Cas 33300-19-5
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com